Skip to main content
. 2017 Mar 15;56(6):631–636. doi: 10.2169/internalmedicine.56.7797

Figure 1.

Figure 1.

The changes in the levels of the serum markers for bone turnover from baseline to 12 months after denosumab therapy. (A) The serum NTX levels were significantly lower 12 months after denosumab therapy than at baseline (from 19.2 to 13.9 nmol BCE/L) (p=0.0003). (B) The serum BAP levels were significantly lower 12 months after denosumab therapy than at baseline (from 11.9 to 9.2 U/L) (p=0.001). Open circles indicate means. #The serum levels of both NTX and BAP were increased in 1 patient.